몰누피라비르 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "몰누피라비르" in Korean language version.

refsWebsite

Global rank Korean rank

4nih.gov

4^th place

4doi.org

2^nd place

3^rd place

2arstechnica.com

388^th place

208^th place

2clinicaltrials.gov

5,225^th place

4,327^th place

1gov.uk

432^nd place

1,006^th place

1science.org

1,160^th place

1,607^th place

1semanticscholar.org

11^th place

310^th place

1acs.org

1,248^th place

442^nd place

1sciencemag.org

857^th place

295^th place

1bnnbloomberg.ca

low place

1web.archive.org

1^st place

1hhs.gov

5,973^rd place

low place

1nytimes.com

7^th place

36^th place

1worldcat.org

5^th place

11^th place

1statnews.com

8,771^st place

7,422^nd place

1washingtonpost.com

34^th place

124^th place

1usatoday.com

41^st place

210^th place

acs.org

cen.acs.org

Halford B. “An emerging antiviral takes aim at COVID-19”. 2020년 8월 1일에 확인함.

arstechnica.com

Mole B (October 2021). “Meet molnupiravir, Merck's Thor-inspired pill that hammers COVID”. 《Ars Technica》. 2021년 10월 2일에 확인함.
Mole B (October 2021). “Meet molnupiravir, Merck's Thor-inspired pill that hammers COVID”. 《Ars Technica》. 2021년 10월 2일에 확인함.

bnnbloomberg.ca

Court E (2020년 7월 31일). “Merck pushes ahead on COVID-19 treatment, vaccines”. 2020년 7월 31일에 확인함.

clinicaltrials.gov

Clinical trial number NCT04575584 for "Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)" - ClinicalTrials.gov
Clinical trial number NCT04575597 for "Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)" - ClinicalTrials.gov

doi.org

dx.doi.org

Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, 외. (October 2019). “Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia”. 《Science Translational Medicine》 11 (515): eaax5866. doi:10.1126/scitranslmed.aax5866. PMC 6848974. PMID 31645453.
Toots M, Yoon JJ, Hart M, Natchus MG, Painter GR, Plemper RK (April 2020). “Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model”. 《Translational Research》 218: 16–28. doi:10.1016/j.trsl.2019.12.002. PMC 7568909. PMID 31945316.
Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NC, 외. (March 2021). “Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2”. 《Antimicrobial Agents and Chemotherapy》 65 (5). doi:10.1128/AAC.02428-20. PMC 8092915. PMID 33649113.
Amara A, Penchala SD, Else L, Hale C, FitzGerald R, Walker L, 외. (September 2021). “The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva”. 《Journal of Pharmaceutical and Biomedical Analysis》 206: 114356. doi:10.1016/j.jpba.2021.114356. PMC 7611757. PMID 34509661. S2CID 237493842.

gov.uk

Medicines and Healthcare products Regulatory Agency (2021년 11월 4일). “First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA”. Goverment of the United Kingdom.

hhs.gov

Division, News (2021년 6월 17일). “Biden Administration to Invest $3 Billion from American Rescue Plan as Part of COVID-19 Antiviral Development Strategy”. 《HHS.gov》 (영어). 2021년 8월 24일에 원본 문서에서 보존된 문서. 2021년 6월 17일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, 외. (October 2019). “Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia”. 《Science Translational Medicine》 11 (515): eaax5866. doi:10.1126/scitranslmed.aax5866. PMC 6848974. PMID 31645453.
Toots M, Yoon JJ, Hart M, Natchus MG, Painter GR, Plemper RK (April 2020). “Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model”. 《Translational Research》 218: 16–28. doi:10.1016/j.trsl.2019.12.002. PMC 7568909. PMID 31945316.
Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NC, 외. (March 2021). “Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2”. 《Antimicrobial Agents and Chemotherapy》 65 (5). doi:10.1128/AAC.02428-20. PMC 8092915. PMID 33649113.
Amara A, Penchala SD, Else L, Hale C, FitzGerald R, Walker L, 외. (September 2021). “The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva”. 《Journal of Pharmaceutical and Biomedical Analysis》 206: 114356. doi:10.1016/j.jpba.2021.114356. PMC 7611757. PMID 34509661. S2CID 237493842.

nytimes.com

Zimmer, Carl (2021년 6월 17일). “A Pill to Treat Covid-19? The U.S. Is Betting on It.”. 《The New York Times》 (미국 영어). ISSN 0362-4331. 2021년 6월 17일에 확인함.

science.org

Lowe, Derek (2021년 10월 13일). “Molnupiravir Mutations”. 《www.science.org》 (영어). Science Magazine. 2021년 10월 13일에 확인함.

sciencemag.org

Cohen J, Piller C (2020년 5월 13일). “Emails offer look into whistleblower charges of cronyism behind potential COVID-19 drug”. Science. 2020년 8월 1일에 확인함.

semanticscholar.org

api.semanticscholar.org

Amara A, Penchala SD, Else L, Hale C, FitzGerald R, Walker L, 외. (September 2021). “The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva”. 《Journal of Pharmaceutical and Biomedical Analysis》 206: 114356. doi:10.1016/j.jpba.2021.114356. PMC 7611757. PMID 34509661. S2CID 237493842.

statnews.com

Herper M (2021년 10월 1일). “Merck's antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment”. 《STAT》. 2021년 10월 2일에 확인함.

usatoday.com

Weintraub K. “New antiviral is highly effective, study finds, and is stirring hope that COVID-19 could be treated by a pill”. 《USA TODAY》. 2021년 10월 3일에 확인함.

washingtonpost.com

“Merck's experimental pill to treat covid-19 cuts risk of hospitalization and death in half, the pharmaceutical company reports”. 《Washington Post》. 2021년 10월 3일에 확인함.

web.archive.org

Division, News (2021년 6월 17일). “Biden Administration to Invest $3 Billion from American Rescue Plan as Part of COVID-19 Antiviral Development Strategy”. 《HHS.gov》 (영어). 2021년 8월 24일에 원본 문서에서 보존된 문서. 2021년 6월 17일에 확인함.

worldcat.org

Zimmer, Carl (2021년 6월 17일). “A Pill to Treat Covid-19? The U.S. Is Betting on It.”. 《The New York Times》 (미국 영어). ISSN 0362-4331. 2021년 6월 17일에 확인함.